Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.

Cassol CA, Bott C, Nadasdy GM, Alberton V, Malvar A, Nagaraja HN, Nadasdy T, Rovin BH, Satoskar AA.

Nephrol Dial Transplant. 2019 Aug 1. pii: gfz152. doi: 10.1093/ndt/gfz152. [Epub ahead of print]

PMID:
31369128
2.

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators.

N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427.

PMID:
31269364
3.

Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease.

Carter SA, Lightstone L, Cattran D, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette R, Malvar A, Radhakrishnan J, Rovin BH, Zhang H, Gutman T, Howell M, Logeman C, Shen JI, Teixeira-Pinto A, Alexander SI, Cho Y, Craig JC, Harris D, Johnson DW, Kerr PG, Ryan J, Viecelli AK, Wang AY, Wilkie M, Scholes-Robertson N, Tong A; SONG-GD Initiative.

Kidney Int. 2019 Jun;95(6):1280-1283. doi: 10.1016/j.kint.2019.01.047. No abstract available.

PMID:
31122702
4.

Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May 10. pii: annrheumdis-2019-215479. doi: 10.1136/annrheumdis-2019-215479. [Epub ahead of print] No abstract available.

PMID:
31076389
5.

The authors reply.

Rovin BH, Solomons N, Huizinga RB.

Kidney Int. 2019 Apr;95(4):992-993. doi: 10.1016/j.kint.2018.12.010. No abstract available.

PMID:
30904071
6.

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal.

Azzouz D, Omarbekova A, Heguy A, Schwudke D, Gisch N, Rovin BH, Caricchio R, Buyon JP, Alekseyenko AV, Silverman GJ.

Ann Rheum Dis. 2019 Jul;78(7):947-956. doi: 10.1136/annrheumdis-2018-214856. Epub 2019 Feb 19.

7.

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J; Conference Participants.

Kidney Int. 2019 Feb;95(2):281-295. doi: 10.1016/j.kint.2018.11.008.

8.

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants.

Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.

PMID:
30665568
9.

Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease.

Rovin BH, Almaani S, Malvar A.

Kidney Int. 2019 Feb;95(2):265-267. doi: 10.1016/j.kint.2018.11.016.

PMID:
30665567
10.

Response to: 'Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jan 18. pii: annrheumdis-2018-214829. doi: 10.1136/annrheumdis-2018-214829. [Epub ahead of print] No abstract available.

PMID:
30659048
11.

Response to: 'ANA testing in "real life"' by Infantino et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Nov 17. pii: annrheumdis-2018-214650. doi: 10.1136/annrheumdis-2018-214650. [Epub ahead of print] No abstract available.

PMID:
30448767
12.

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group.

Kidney Int. 2019 Jan;95(1):219-231. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9.

PMID:
30420324
13.

Zonal cortical scarring and tubular thyroidization in kidney biopsies of patients with SLE-histologic indicator for antiphospholipid antibodies.

Shah R, Brodsky SV, Hebert L, Rovin BH, Nadasdy T, Satoskar AA.

Lupus. 2018 Dec;27(14):2236-2244. doi: 10.1177/0961203318809177. Epub 2018 Nov 7.

PMID:
30403144
14.

Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.

Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Solomons N, Houssiau FA, Romero-Diaz J, Mejia-Vilet J, Rovin BH.

Arthritis Rheumatol. 2019 Mar;71(3):411-419. doi: 10.1002/art.40724. Epub 2019 Feb 1.

PMID:
30225865
15.

B-cell therapy in lupus nephritis: an overview.

Almaani S, Rovin BH.

Nephrol Dial Transplant. 2019 Jan 1;34(1):22-29. doi: 10.1093/ndt/gfy267.

PMID:
30165690
16.

Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease in type 1 diabetes.

Looker HC, Merchant ML, Rane MJ, Nelson RG, Kimmel PL, Rovin BH, Klein JB, Mauer M; CKD Biomarkers Consortium.

Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1484-F1492. doi: 10.1152/ajprenal.00183.2018. Epub 2018 Aug 22.

PMID:
30132343
17.

Induction Therapy for Lupus Nephritis: the Highlights.

Ayoub I, Nelson J, Rovin BH.

Curr Rheumatol Rep. 2018 Aug 14;20(10):60. doi: 10.1007/s11926-018-0766-9. Review.

PMID:
30109511
18.

A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.

De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, Nash R, Rovin BH.

Kidney Int. 2018 Oct;94(4):788-794. doi: 10.1016/j.kint.2018.05.021. Epub 2018 Jul 23.

PMID:
30045812
19.

Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Aug;78(8):e77. doi: 10.1136/annrheumdis-2018-213841. Epub 2018 Jun 23. No abstract available.

PMID:
29936440
20.

Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare.

Mejia-Vilet JM, Parikh SV, Song H, Fadda P, Shapiro JP, Ayoub I, Yu L, Zhang J, Uribe-Uribe N, Rovin BH.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1197-1206. doi: 10.1093/ndt/gfy125.

PMID:
29800348
21.

Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e51. doi: 10.1136/annrheumdis-2018-213582. Epub 2018 May 5. No abstract available.

PMID:
29730639
22.

Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e49. doi: 10.1136/annrheumdis-2018-213558. Epub 2018 May 5. No abstract available.

PMID:
29730638
23.

Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e47. doi: 10.1136/annrheumdis-2018-213537. Epub 2018 Apr 28. No abstract available.

PMID:
29705742
24.

Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May;78(5):e34. doi: 10.1136/annrheumdis-2018-213399. Epub 2018 Mar 28. No abstract available.

PMID:
29592916
25.

Screening for cognitive impairment in SLE using the Self-Administered Gerocognitive Exam.

Meara A, Davidson N, Steigelman H, Zhao S, Brock G, Jarjour WN, Rovin BH, Madhoun H, Parikh S, Hebert L, Ayoub I, Ardoin SP.

Lupus. 2018 Jul;27(8):1363-1367. doi: 10.1177/0961203318759429. Epub 2018 Feb 21.

PMID:
29466913
26.

Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Jun;77(6):911-913. doi: 10.1136/annrheumdis-2017-212599. Epub 2018 Feb 9.

PMID:
29440000
27.

Characterization and classification of lupus patients based on plasma thermograms.

Garbett NC, Brock GN, Chaires JB, Mekmaysy CS, DeLeeuw L, Sivils KL, Harley JB, Rovin BH, Kulasekera KB, Jarjour WN.

PLoS One. 2017 Nov 17;12(11):e0186398. doi: 10.1371/journal.pone.0186398. eCollection 2017.

28.

Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy.

Alvarado AS, Andeen NK, Brodsky S, Hinton A, Nadasdy T, Alpers CE, Blosser C, Najafian B, Rovin BH.

Nephrol Dial Transplant. 2018 Jul 1;33(7):1168-1175. doi: 10.1093/ndt/gfx238.

29.

Calcineurin Inhibitors in the Treatment of Lupus Nephritis: A Hare Versus Turtle Story?

Ayoub I, Rovin BH.

J Am Soc Nephrol. 2017 Dec;28(12):3435-3437. doi: 10.1681/ASN.2017080830. Epub 2017 Oct 5. No abstract available.

30.

Reply.

Rovin BH, Birmingham D, Cartin-Ceba R, Specks U, Stone JH.

Arthritis Rheumatol. 2017 Nov;69(11):2247-2248. doi: 10.1002/art.40220. No abstract available.

31.

Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus.

Wheelock KM, Cai J, Looker HC, Merchant ML, Nelson RG, Fufaa GD, Weil EJ, Feldman HI, Vasan RS, Kimmel PL, Rovin BH, Mauer M, Klein JB; CKD Biomarkers Consortium.

PLoS One. 2017 Jul 10;12(7):e0180964. doi: 10.1371/journal.pone.0180964. eCollection 2017.

32.

Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy.

Cardenas-Gonzalez M, Srivastava A, Pavkovic M, Bijol V, Rennke HG, Stillman IE, Zhang X, Parikh S, Rovin BH, Afkarian M, de Boer IH, Himmelfarb J, Waikar SS, Vaidya VS.

Clin Chem. 2017 Sep;63(9):1515-1526. doi: 10.1373/clinchem.2017.274175. Epub 2017 Jun 30.

33.

Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise.

Birmingham DJ, Merchant M, Waikar SS, Nagaraja H, Klein JB, Rovin BH.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i71-i79. doi: 10.1093/ndt/gfw300. Review.

34.

Reply.

Rovin BH, Birmingham D, Cartin-Ceba R, Specks U, Stone JH.

Arthritis Rheumatol. 2017 Jul;69(7):1507-1508. doi: 10.1002/art.40121. Epub 2017 May 31. No abstract available.

35.

A proposal for standardized grading of chronic changes in native kidney biopsy specimens.

Sethi S, D'Agati VD, Nast CC, Fogo AB, De Vriese AS, Markowitz GS, Glassock RJ, Fervenza FC, Seshan SV, Rule A, Racusen LC, Radhakrishnan J, Winearls CG, Appel GB, Bajema IM, Chang A, Colvin RB, Cook HT, Hariharan S, Herrera Hernandez LP, Kambham N, Mengel M, Nath KA, Rennke HG, Ronco P, Rovin BH, Haas M.

Kidney Int. 2017 Apr;91(4):787-789. doi: 10.1016/j.kint.2017.01.002.

PMID:
28314581
36.

The Urine Preservative Acetic Acid Degrades Urine Protein: Implications for Urine Biorepositories and the AASK Cohort Study.

Almaani S, Hebert LA, Rovin BH, Birmingham DJ.

J Am Soc Nephrol. 2017 May;28(5):1394-1398. doi: 10.1681/ASN.2016080886. Epub 2017 Jan 19.

37.

New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA.

Pisetsky DS, Rovin BH, Lipsky PE.

Arthritis Rheumatol. 2017 Mar;69(3):487-493. doi: 10.1002/art.40008. Review. No abstract available.

38.

Molecular imaging of the kidney in lupus nephritis to characterize response to treatment.

Parikh SV, Malvar A, Song H, Alberton V, Lococo B, Vance J, Zhang J, Yu L, Birmingham D, Rovin BH.

Transl Res. 2017 Apr;182:1-13. doi: 10.1016/j.trsl.2016.10.010. Epub 2016 Nov 1.

39.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.

J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.

40.

Update on Lupus Nephritis.

Almaani S, Meara A, Rovin BH.

Clin J Am Soc Nephrol. 2017 May 8;12(5):825-835. doi: 10.2215/CJN.05780616. Epub 2016 Nov 7. Review.

41.

The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials.

Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW.

Lupus. 2016 Dec;25(14):1597-1601. Epub 2016 May 24.

PMID:
27220348
42.

The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Cartin-Ceba R, Indrakanti D, Specks U, Stone JH, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Spiera RF, Monach PA, St Clair EW, Seo P, Tchao NK, Ytterberg SR, Brunetta PG, Song H, Birmingham D, Rovin BH; RAVE-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2017 Jan;69(1):169-175. doi: 10.1002/art.39822.

43.

The interleukin-6-hepcidin-hemoglobin circuit in systemic lupus erythematosus flares.

Indrakanti DL, Alvarado A, Zhang X, Birmingham DJ, Hinton A, Rovin BH.

Lupus. 2017 Feb;26(2):200-203. doi: 10.1177/0961203316659153. Epub 2016 Jul 20.

44.

Current and Emerging Therapies for Lupus Nephritis.

Parikh SV, Rovin BH.

J Am Soc Nephrol. 2016 Oct;27(10):2929-2939. Epub 2016 Jun 9. Review.

45.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.

Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, Belkowski S, Hsu B.

Arthritis Rheumatol. 2016 Sep;68(9):2174-83. doi: 10.1002/art.39722.

46.

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Ayoub I, Hebert L, Rovin BH.

N Engl J Med. 2016 Mar 10;374(10):991-2. doi: 10.1056/NEJMc1600141. No abstract available.

PMID:
26962738
47.

Predicting decline of kidney function in lupus nephritis using urine biomarkers.

Abulaban KM, Song H, Zhang X, Kimmel PL, Kusek JW, Nelson RG, Feldman HI, Vasan RS, Ying J, Mauer M, Nelsestuen GL, Bennett M, Brunner HI, Rovin BH.

Lupus. 2016 Aug;25(9):1012-8. doi: 10.1177/0961203316631629. Epub 2016 Feb 11.

48.

Hurdles to the introduction of new therapies for immune-mediated kidney diseases.

Anders HJ, Jayne DR, Rovin BH.

Nat Rev Nephrol. 2016 Apr;12(4):205-16. doi: 10.1038/nrneph.2015.206. Epub 2016 Jan 25. Review.

PMID:
26804020
49.

Quiz Page February 2016: Acute Kidney Injury in a Patient With Granulomatosis With Polyangiitis Receiving Maintenance Immunosuppressive Therapy.

Ayoub I, Almaani S, Alvarado A, Parikh SV, Rovin BH.

Am J Kidney Dis. 2016 Feb;67(2):A20-3. doi: 10.1053/j.ajkd.2015.10.017. No abstract available.

PMID:
26802333
50.

Prospective validation of a novel renal activity index of lupus nephritis.

Gulati G, Bennett MR, Abulaban K, Song H, Zhang X, Ma Q, Brodsky SV, Nadasdy T, Haffner C, Wiley K, Ardoin SP, Devarajan P, Ying J, Rovin BH, Brunner HI.

Lupus. 2017 Aug;26(9):927-936. doi: 10.1177/0961203316684212. Epub 2016 Dec 19.

Supplemental Content

Loading ...
Support Center